HomeNewsBusinessMarketsBe selective with IT & pharma; positive on Divi's Labs, DRL, Biocon: Vipin Khare

Be selective with IT & pharma; positive on Divi's Labs, DRL, Biocon: Vipin Khare

Investors should be selective with IT and Pharma. And, in the pharma space, William O'Neil India is more constructive on Divi’s Laboratories, Dr. Reddy, and Biocon which look good to us.

November 29, 2018 / 17:18 IST
Story continues below Advertisement

We believe investors should be selective with IT and pharma sector. And in the pharma space, we are more constructive on Divi’s Laboratories, Dr. Reddy and Biocon, Vipin Khare, Director- Research, William O'Neil India, said in an interview with Moneycontrol’s Kshitij Anand.

Q) Do you think that the recent bounce was largely on the back of rupee appreciation and fall in crude oil prices and the rally is short-lived?

Story continues below Advertisement

A) Over the last three weeks, the Indian market has been resilient. Private banks supported the Nifty Bank after PSUs took a breather and ended flat for the week ended November 22.

So far, we have seen good action in Eicher Motors, ICICI Bank and Havells India. Currently, the Nifty is trading about 1 percent below its 200-DMA and we will get a strong conviction about the current rally once it crosses that level.